All In Biotech

Drug Trial Radar · NCT01147640

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections

Last checked: Nov 20, 2026Latest source record: Oct 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

122

Actual

Start

Jun 25, 2010

Primary completion

Feb 20, 2011

Study completion Mar 25, 2011

Sponsor

Sponsor type
Industry
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs. meropenem IV infusion (1000 mg q8h) and a matching saline placebo (q8h) in the treatment of cIAI in adult subjects. Dose adjustments for subjects with mild renal impairment are not necessary and subjects with more severe degrees of renal failure are excluded.

Conditions

  • Complicated Intra-abdominal Infection

Interventions

  • CXA-101/ tazobactam and metronidazoleDrug

    CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion

  • meropenem plus saline placeboDrug

    meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis PopulationTime frame: Test-of-Cure Visit (7-14 days after End of Therapy [EOT])

Locations

33 sites in 5 countries. Site status is shown where the registry gives one.

  • Pulmonary Consultants and Primary Care Physicians Medical Group, Inc.

    Orange, California

  • Los Angeles Biomedical Research Institue at Harbor UCLA Medical Center

    Torrance, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Christiana Care Health System

    Newark, Delaware

  • Pensacola Research Consultants, Inc.

    Pensacola, Florida

  • Henry Ford Hospital

    Detroit, Michigan

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • Metro Health Medical Center

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • University of Tennessee Health Science Center

    Memphis, Tennessee

  • Sanatorio Guemes

    C.a.b.a., Argentina

  • Hospital Nuestra Señora de la Misericordia

    Córdoba, Argentina

  • Hospital San Roque

    Córdoba, Argentina

  • Hospital Central de Mendoza

    Mendoza, Argentina

  • Hospital Dr. José María Cullen

    Santa Fe, Argentina

  • Hospital San Martín

    Paraná, Entre Ríos Province, Argentina

  • Ltd Ivane Javakhishvili Tbilisi State University Center

    Tbilisi, Georgia

  • JSC K.Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Ltd Vakhtang Bochorishvili Antiseptic Center

    Tbilisi, Georgia

  • Tbilisi State Hospital #4

    Tbilisi, Georgia

  • Federal State Institution

    Moscow, Russia

  • State Moscow Healthcare

    Moscow, Russia

  • State Healthcare Institution

    Moscow, Russia

  • Municipal Healthcare Institution "City Clinical Hospital #2"

    Novosibirsk, Russia

  • Regional State Healthcare

    Novosibirsk, Russia

  • State Healthcare Institution

    Saint Petersburg, Russia

  • State Educational Institution of Higher Professional Education

    Saint Petersburg, Russia

  • Saint Petersburg State Healthcare Institution "City Hospital # 26"

    Saint Petersburg, Russia

  • Clinical Hospital Centre Zvezdara

    Belgrade, Serbia

  • Emergency Centre, Clinical Centre of Serbia

    Belgrade, Serbia

  • Clincal Centre Nis

    Niš, Serbia

  • Clinical Centre of Vojvodina

    Novi Sad, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.